Osaka University Graduate School of Medicine, Department of Cardiovascular Surgery, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Gen Thorac Cardiovasc Surg. 2021 May;69(5):859-861. doi: 10.1007/s11748-020-01540-x. Epub 2020 Nov 7.
In children with dilated cardiomyopathy, heart transplantation is the last treatment option. However, new regenerative treatments, such as cell therapy, have attracted scientific attention. We have previously demonstrated the efficacy of autologous skeletal myoblast sheet implantation for treatment of ischemic and dilated cardiomyopathy in adults. Because of the mechanism underlying this cell therapy, a similar effectiveness is expected for patients with pediatric dilated cardiomyopathy.
Herein, we describe the case of a child with dilated cardiomyopathy who underwent an autologous skeletal myoblast sheet implantation, which proved to be safe, and led to sustained maintenance and improvements in cardiac function and clinical status.
在患有扩张型心肌病的儿童中,心脏移植是最后的治疗选择。然而,新的再生治疗方法,如细胞疗法,已经引起了科学界的关注。我们之前已经证明了自体骨骼肌母细胞片移植治疗成人缺血性和扩张型心肌病的疗效。由于这种细胞疗法的作用机制,预计对于患有儿科扩张型心肌病的患者也具有类似的疗效。
在此,我们描述了一例接受自体骨骼肌母细胞片移植的扩张型心肌病患儿的病例,该手术证明是安全的,并持续维持和改善了心脏功能和临床状况。